PATENT CLAIM ANALYSIS

Application Number: 16186879
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-02
Patent Classification: ["514", "001400"]

Abstract:
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.

Claim (Index 43):
The use of a therapeutically effective amount of a melanocortin-4 receptor agonist or antagonist according to any one of  claims 1  to  6 , or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to modulate ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection, nerve growth, bone metabolism, bone formation and bone development.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.46875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12602010', '14024961', '13074565', '11988468', '15055873']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8863159272983555
- 35 USC 102 Novelty (BERT): 0.6193007791393419
- Combined Prediction Score: 0.8596144124824542
- Mean Citation Score: 625.486862
- Max Citation Score: 672.6033
- Similarity Product: 489.4881362576365

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test